期刊文献+

非小细胞肺癌中缺氧诱导因子-1α和p-糖蛋白的表达及其与人乳头状瘤病毒感染的相关性 被引量:14

Expression of HIF-1α and p-gp in non-small cell lung cancer and their relationship with HPV infection
下载PDF
导出
摘要 目的缺氧诱导因子-1α(hypoxia inducible factor-1α,HIF-1α)、p-糖蛋白(p-glycoprotein,p-gp)的表达,HPV感染在非小细胞肺癌(non-small cell lung cancer,NSCLC)发生发展中的作用及三者的相互关系尚不清楚。文中研究NSCLC中HIF-1α和p-gp的相关性,探讨HIF-1α和p-gp在NSCLC发生发展及多药耐药(multidrug resistance,MDR)中的作用,并初步分析HIF-1α和p-gp与人乳头状瘤病毒(human papillomavirus,HPV)感染的相关性。方法收集秦皇岛市第一医院2012年1-5月NSCLC新鲜标本60例作为NSCLC组,20例肺良性病变组织作为肺良性病变组,应用PCR方法选用HPV16、18型特异性引物检测2组中HPV DNA的表达,应用免疫组化法检测HIF-1α、p-gp的表达。结果 NSCLC中HIF-1α阳性率为48.3%(29/60),肺良性病变未见阳性表达(χ2=15.163,P<0.05);p-gp的阳性率为60.0%(36/60),肺良性病变未见阳性表达(χ2=21.818,P<0.05);HIF-1α阳性者中p-gp的表达率明显高于HIF-1α阴性者,两者呈正相关(r=0.313,P<0.05);NSCLC组中HIF-1α表达与组织分化程度及淋巴结转移相关;p-gp表达与组织学分型相关,肺腺癌p-gp阳性表达率(83.3%)高于肺鳞癌(50.0%),差异有统计学意义(P<0.05)。NSCLC高分化型HPV DNA检出率(8.3%)低于中、低分化型(50.0%),差异有统计学意义(P<0.05)。淋巴结转移者HPV DNA检出率(60.6%)高于无淋巴结转移者(23.3%),差异有统计学意义(P<0.05)。结论 HIF-1α与p-gp参与了NSCLC的发生发展及MDR;HPV感染可能是NSCLC发生的病因学因素之一,但NSCLC中HIF-1α、p-gp表达与HPV感染均无协同作用。 Objective The effect of hypoxia inducible factor-1α( HIF-1α) , p-glycoprotein ( p-gp) and human papillomavir-us(HPV) infection on non-small cell lung cancer (NSCLC) and their interrelationship are still not clear .The article aimed to study the relationship between HIF-1αand P-gp, their role in the occurrence , development and multidrug resistance of NSCLC , as well as the in-terrelationship among HIF-1α, p-gp expression and HPV infection . Methods By using immunohistochemistry , the expression of HIF-1αand p-gp was detected in 60 NSCLC tissues and 20 benign lung disease tissues .PCR was employed to detect the expression of HPV16/18 DNA. Results The positive expression rate of HIF-1αand p-gp was 48.3% and 60.0% respectively in NSCLC, but there was no positive expression of HIF-1αand p-gp detected in the benign lung disease group (P〈0.05).The positive expression rate of p-gp in HPV DNA positive group and negative group was 64.0% and 57.1%respectively, which showed no significant difference too (P〉0.05). Conclusion HIF-1αand p-gp are involved in the occurrence, development and multidrug resistance of NSCLC .HPV infection may be one of the etiological factors in the carcinogenesis of NSCLC . However , neither the HIF-1αexpression nor the p-gp expression is associated with HPV infection .
出处 《医学研究生学报》 CAS 北大核心 2014年第10期1069-1072,共4页 Journal of Medical Postgraduates
基金 秦皇岛市科学技术研究与发展计划(2012023A135)
关键词 非小细胞肺癌 缺氧诱导因子-1Α P-糖蛋白 人乳头状瘤病毒 Non-small cell lung cancer Hypoxia inducible factor-1α P-glycoprotein Human papillomavirus
  • 相关文献

参考文献16

二级参考文献47

  • 1Maxwell PH. The HIF pathway in cancer [ J ]. Semin Cell Dev Biol, 2005, 16(4 -5) :523 -530.
  • 2Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor-lalpha and-2alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival[ J]. Br J Cancer, 2001, 85 (6) :881 -890.
  • 3Mizokami K, Kakeji Y, Oda S,et al. Clinicopathologic significance of hypoxia-inducible factor-1 alpha overexpression in gastric carcinomas [ J ]. Surg Oncol, 2006, 94 ( 2 ) : 149 - 154.
  • 4Rohwer N, Lobitz S, Daskalow K, et al. HIF-1 alpha determines the metastatic potential of gastric cancer cells[J]. Br J Cancer,2009, 100(5) :772-781.
  • 5Song IS, Wang AG, Yoon SY, et al. Regulation of glucose metabolism-related genes and VEGF by HIF-1alpha and HIF-1 beta, but not HIF-2alpha, in gastric cancer [ J ]. Exp Mol Med, 2009, 41(1):51 -58.
  • 6Coussens L, Yang-feng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene[J]. Scinece, 1985,230(12):1132-1139.
  • 7Bacci G, Ferrari S, Bertoni F et al, Long-term outcome for patients with nonmetastatic osteosarcoma of the exthemity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/ osteosarcoma-2 protocol: an update report[J]. J Clin Oncol, 2000,18(24):4016-4027.
  • 8Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-p185HER2 monoclonal antibody in women who have HER2-overexpression metastatic breast cancer that has progressed after chemotherapy for metastatic disease[J]. J Clin Oncol, 1999,17(9):2639-2648.
  • 9Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11):783-792.
  • 10Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification[J]. J Clin Oncol, 2001,19(10):2587-2595.

共引文献40

同被引文献161

引证文献14

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部